top of page

Survey of CBG Patients (October 2022)

Updated: Dec 7, 2022

Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.


An October 2022 study entitled "Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms" that was published in the journal Cannabis and Cannabinoid Research explored the potential medicinal efficacy of the cannabis- and hemp-derived cannabinoid cannabigerol (CBG).

The study's authors—who included cannabis research pioneer Dr. Ethan Russo—stated that the purpose of their scientific investigation was to explore "reasons for use and self-reported therapeutic effects in CBG-predominant cannabis users." The researchers observed CBG usage patterns and looked for potential adverse effects, including withdrawal symptoms (spoiler: very found were found).


Study Conclusions

"Most of the participants (51%) reported use of CBG-predominant products solely for medical purposes (36% reported use for medical and recreational purposes; 6% reported recreational use only).


The most common conditions the study subjects reported using CBG to treat were:

  1. Anxiety (51%)

  2. Chronic pain (41%)

  3. Depression (33%)

  4. Insomnia/disturbed sleep (31%)

Efficacy was highly rated, with the majority reporting their conditions were 'very much improved' or 'much improved' by CBG. Furthermore, [many study participants] claimed superiority of CBG-predominant cannabis over conventional medicines for:

  1. Chronic pain (74%)

  2. Depression (80%)

  3. Insomnia (73%)

  4. Anxiety (78%)

Forty-four percent of CBG-predominant cannabis users reported no adverse events, with [the following adverse events]:

  1. Dry mouth (17%)

  2. Sleepiness (15%)

  3. Increased appetite (12%)

  4. Dry eyes (9%)

CBG molecular structure


"Around 84% reported no withdrawal symptoms, with sleep difficulties representing the most frequently endorsed withdrawal symptom (endorsed by two respondents).


"Perceived efficacy was highly rated, with the majority reporting their conditions were 'very much improved' or 'much improved' by CBG."

"This is the first patient survey of CBG-predominant cannabis use to date and the first to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign (safe) adverse event profile and negligible withdrawal symptoms.


"This study establishes that humans are employing CBG and suggests that CBG-predominant cannabis-based medicines should be studied in randomized controlled trials."


View the original study.


🎧 Like what you just read? Listen and learn with our highly educational weekly Cannabis Commerce + Chemistry Podcast. At under 30 minutes per episode, it helps industry professionals stay current on trending topics.

67 views0 comments

Recent Posts

See All
bottom of page